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Abstract
Background and Purpose: Ashwagandha is a popular Ayurvedic herb used in Indian traditional home medicine. It has been
assigned a variety of health-promoting effects of which the mechanisms remain unknown. We previously reported the
selective killing of cancer cells by leaf extract of Ashwagandha (i-Extract) and its purified component Withanone. In the
present study, we investigated its mechanism by loss-of-function screening (abrogation of i-Extract induced cancer cell
killing) of the cellular targets and gene pathways.
Methodology/Principal Findings: Randomized ribozyme library was introduced into cancer cells prior to the treatment with
i-Extract. Ribozymes were recovered from cells that survived the i-Extract treatment. Gene targets of the selected ribozymes
(as predicted by database search) were analyzed by bioinformatics and pathway analyses. The targets were validated for
their role in i-Extract induced selective killing of cancer cells by biochemical and molecular assays. Fifteen gene-targets were
identified and were investigated for their role in specific cancer cell killing activity of i-Extract and its two major components
(Withaferin A and Withanone) by undertaking the shRNA-mediated gene silencing approach. Bioinformatics on the selected
gene-targets revealed the involvement of p53, apoptosis and insulin/IGF signaling pathways linked to the ROS signaling. We
examined the involvement of ROS-signaling components (ROS levels, DNA damage, mitochondrial structure and membrane
potential) and demonstrate that the selective killing of cancer cells is mediated by induction of oxidative stress.
Conclusion: Ashwagandha leaf extract and Withanone cause selective killing of cancer cells by induction of ROS-signaling
and hence are potential reagents that could be recruited for ROS-mediated cancer chemotherapy.
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Introduction
Indian traditional home medicine system, Ayurveda is renown
for its oldest history in the world. Ashwagandha (Withania somnifera;
Solanaceae) herb, proudly called Queen of Ayurveda, is one of the
most commonly used plants in Ayurveda for a variety of effects
that range from analgesic, astringent, adaptogen, anti-inflamma-
tory, anti-stress, antispasmodic, anti-diabetes, immuno-stimulant
and cardioprotective [1–4]. Extracts from different parts of the
plant including root, shoot, seed and berry have been in use in
various home-remedy recipes; root being particularly a common
source for health-promoting alkaloids, withanolides and antioxi-
dants. The main active constituents of Ashwagandha leaves are
alkaloids and steroidal lactones (commonly known as With-
anolides) [5–7]. We had previously investigated the biological
activity in an alcoholic extract of Ashwagandha leaf extract (i-
Extract) and demonstrated that it has a strong anti-cancer activity.
By chemical fractionation, the activity was assigned to its
constituent Withanone (i-Factor) that was shown to cause
activation of tumor suppressor protein p53 in cancer cells only
[8,9]. Normal human fibroblasts showed down-regulation of p53
function and delayed senescence [10].
In the present study, we anticipated that the selective
cancer cell-killing effect of i-Extract or Withanone is likely to
be mediated by more than one genes/pathways and hence
undertook an unbiased loss-of-function approach wherein gene
knockdown was achieved by hammerhead ribozymes. Ribo-
zyme population rescued from randomized ribozyme library-
infected human breast cancer cells that survived the i-Extract
treatment was characterized. Bioinformatics, biochemical and
visual assays were employed to investigate the identified gene
targets and to reveal their involvement in i-Extract-induced
cancer cell killing. We demonstrate that the selective killing of
cancer cells by i-Extract and its component Withanone involves
ROS signaling.
Results and Discussion
Hammerhead ribozymes (HH-Rz) are the small catalytic RNAs
that possess conserved hammerhead like secondary structure.
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and hydrolyze phosphodiester bonds of RNA strands at specific
sites (NUX, where N can be any nucleotide and X can be A, C or
U) and hence are known as ‘‘RNA scissors’’ [11,12]. HH-Rz have
been in use as gene- silencing tools due to their features such as,
high substrate binding specificity, autocatalytic activity that does
not require other enzymes, flexible structure allowing manipula-
tions and lack of interferon response in mammalian cells [13,14].
In order to generate a gene specific ribozyme, its recognition arms
(7–9 nucleotides flanking the target site) are designed to include
sequence complementary to the target mRNA. Randomization of
these 7–9 nucleotides in each arm yields a large variety of
ribozyme capable of targeting multiple mRNA substrates [11].
Such pool of degenerate ribozymes expressed from an exogenous
promoter has been used as a tool for identification of genes
involved in apoptosis, migration, invasion, differentiation and
diseases [15–20]. In order to identify the cellular targets involved
in cancer cell cytotoxity of Ashwagandha leaf extract (i-Extract),
we infected the MCF7 cells with retrovirus driven randomized
ribozyme library prior to the treatment. As shown in Figure 1,
Figure 1. Screening for gene targets involved in i-Extract induced cyto-toxicity. Schematic presentation of loss-of-function screening using
randomized ribozyme library. Control cells treated with i-Extract showed cytotoxicity (A). i-Extract treated surviving cells were collected (B). Ribozymes
were rescued from the surviving cells by cloning and were characterized by sequence analysis (B). Candidate gene targets are shown in (C).
doi:10.1371/journal.pone.0013536.g001
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in cell death, ribozyme library infected culture showed cell
survival. Ribozymes were rescued from these surviving cell
population and characterized by cloning and sequence analysis.
Gene targets for the isolated ribozyme sequences were determined
by database search (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The
potential gene targets of the ribozyme sequences that were isolated
multiple times are listed in Figure 1C. In order to validate the
involvement of these genes in i-Extract induced cancer cell killing,
we undertook two-way analyses (i) gene specific shRNA-mediated
silencing and (ii) bioinformatics and systems biology directed
pathway investigation. We prepared 7 gene (IGF2R, SREBF2,
AKAP11, TFAP2A, LHX3, TPX2 and ING1) specific shRNAs
and investigated their involvement in i-Extract and its components
(Withanone and Withaferin A) induced MCF7 cell killing. Even
under the efficiency of transfection ranging from 40–60%, as
determined by transfection of a GFP-expressing plasmid, silencing
of four genes (Group 1 - TPX2, ING1, TFAP2A and LHX3) was
associated with significant (20–40%) increase in cell survival
subsequent to the i-Extract treatment (Figure 2). The other three
genes (Group 2 - IGF2R, SREBF2 and AKAP11) showed only
minor (2–8%) increase in survival. Furthermore, cells compro-
mised for the expression of four Group 1 genes escaped the
cytotoxic effect of both Withanone and Withaferin A. These data
suggested that these four genes mediate the cytotoxicity of i-
Extract. However, they may not be critically involved in selective
toxicity of i-Extract and Withanone to cancer cells as described in
our earlier studies demonstrating the involvement of p53 tumor
suppressor pathway in this phenomenon [8]. These data indicated
that the cancer cell killing by i-Extract was mediated, at least in
part, by TPX2, ING1, TFAP2A and LHX3. TPX2 is a
microtubule-associated protein that functions as an allosteric
regulator of Aurora-A, an oncogene with essential role in
centrosome maturation and chromosome segregation during
mitosis requiring assembly and maintenance of a bipolar spindle
[21–23]. It is overexpressed in multiple human cancers and has
been proposed as an attractive anti-cancer target [24]. TFAP2A
plays crucial role in tumor growth and progression by regulation of
E-cadherin, MMP-2, c-kit, p21
WAF-1, HER-2, BCL-2, insulin like
growth factor receptor-1 and Smad signaling [25]. LHX3 is a
homeodomain transcription factor and plays positive role in
embryonic development, cell fate determination and oncogenesis
[26,27]. On the other hand, ING1, an ING family protein, is
involved in human cellular senescence, tumor suppression and
apoptosis [28,29]. ING1 has been shown to modulate p53 activity
and its downstream effectors, p21
WAF1 and Bax by acetylation and
stabilization [30]. Taken together, the data suggested that the
cancer cell killing by i-Extract might involve repression of TPX2,
Figure 2. Effect of shRNA-mediated gene silencing on i-Extract induced cytotoxicity. Cells were transfected with vectors expressing shRNA
for indicated genes. The effect of i-Extract was evaluated by cell viability assay. Results represent the mean of three experiments. Statistical
significance was calculated by Analysis Of Variance (ANOVA) test.
doi:10.1371/journal.pone.0013536.g002
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mechanism and selectivity to cancer cells still remian unclear.
In order to identify crucial cellular targets, we next undertook
bioinformatics and systems biology approach and examined the
network/pathways of the identified gene targets described above
(Figure 3). The analyses revealed the involvement of isolated gene
targets in several kinds of biological processes such as, oncogenesis,
cell cycle, DNA repair and nucleic acid metabolism (Figure 3A).
The top two identified pathways were p53 tumor suppressor (gene
targets - DDB2, CDKN1A, CDKN2B) and apoptosis (gene targets
- IGF2R and HSPA9). Of note, the analyses indicated that 33% of
the genes involved in p53 pathway and its regulation, and 7% of
the genes involved in apoptosis were identified suggesting that the
cell killing by i-Extract involves growth arrest or apoptosis,
mediated by activation of tumor suppressor p53 pathway. In
addition, Ras, insulin/IGF, angiogenesis and cytoskeleton regula-
tion pathways that are tightly linked with apoptosis and tumor
development were also identified. These results demonstrated that
the silencing of target genes abrogate the i-Extract mediated cell
killing by protecting the cells from DNA damage, cell cycle arrest
and apoptosis. Network interaction analysis of the target genes
conceived four gene clusters - CDK4, TFAP2A, CDKN1A-p21
Figure 3. Bioinformatics analyses of the selected gene targets. Biological processes that were involved in i-Extract mediated cell death were
predicted to include oncogenesis, cell proliferation and cell cycle (A) and involved p53, apoptosis, and insulin/IGF signaling pathways (B). Most
predominant amongst these pathways were p53 and apoptosis (C). The target genes appeared as four clusters (CDK4, p21, ING1 and TFAP2A) that
were connected by p53 and PCNA, involved in cell cycle, DNA damage response and DNA repair gene (D). Based on the selected gene targets, it was
predicted that the i-Extract mediated cancer cell killing involved ROS- mediated damage at DNA and mitochondrial level with CDKN1A as a critical
mediator (E).
doi:10.1371/journal.pone.0013536.g003
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clusters during i-Extract induced cytotoxicity suggests that it might
be characterized as cellular responses, including stress response
(HSPA9, CDKN1A) and DNA damage and repair response
(ING1, DDB2 and TFAP2A), culminating into either cell cycle
arrest or apoptosis (Figure 3D). Based on these parameters
identified by bioinformatics analysis, we predicted that the i-
Extract might cause an activation of cellular stress signaling by
ROS-mediated pathways initiated at two levels (i) mitochondrial
stress leading to change in membrane potential and (ii) DNA
damage stress leading to activation of DNA damage and repair
machinery (Figure 3E). Of note, most of the identified gene targets
seemed to fit into the predicted signaling pathways (Figure 3E). In
order to test this hypothesis, we investigated whether CDKNIA-
p21 is the critical regulator of the i-Extract mediated cancer cell
killing. As shown in Figure 4, i-Extract mediated growth arrest in
MCF7 cells (Figure 4A) was associated with an activation of
CDKN1A-p21 (Figure 4B). We also investigated to examine
whether CDKN1A-p21 was a critical mediator of i-Extract
induced selective cancer cell killing. As shown in Figures 4B and
4C, whereas CDKN1A-p21 was increased in MCF7 cells, it
remained unaltered in normal (TIG-3) cells in response to either i-
Extract or Withanone treatment. In contrast, Withaferin A caused
cytotoxicity to both cancer and normal cell and was seen to
activate CDKN1A-p21 (Figure 4C). We next investigated the
activation of CDKN1A-p21 in control and i-Extract treated
MCF7 cells following the transfections of four shRNAs that
abrogated i-Extract induced MCF7 cell killing, at least in part
(Figure 2). As shown in Figures 4D and 4E, we found that the i-
Extract induced increase in CDKN1A-p21 expression was
abrogated by knockdown of each of these four target genes. These
data demonstrated that the CDKN1A-p21 is a critical mediator of
i-Extract induced selective growth arrest in cancer cells. We finally





2/2 HCT116 colon cancer cells. We found that
whereas p53
+/+ and p53
2/2 cells showed comparable sensitivity to
i-Extract (data not shown), the p21
2/2 cells were two-three times
more tolerant to i-Extract treatment as compared to the p21
+/+
cells (Figure 4F) endorsing that CDKN1A-p21 is indeed a vital
mediator of the growth arrest induced by i-Extract in cancer cells.
The data was consistent with our model proposed in Figure 3E.
As predicted by pathway analysis (Figure 3E), we next
investigated the involvement of DNA damage and repair-signaling
pathway in i-Extract induced cancer cell killing. As shown, MCF7
cells showed induction of cH2AX (an early marker of DNA
damage response) in response to the treatment with i-Extract,
Withaferin A and Withanone (Figures 5A and 5B). We also
examined the phosphorylation of cH2AX by immunostaining with
a phosphorylation specific antibody and found that the number of
cells containing phosphorylated cH2AX was 70% higher in i-
Extract treated cells as compared to the control (Figure 5B).
Whereas the Withaferin A treatment induced cH2AX in both
normal and cancer cells, i-Extract and Withanone induced
cH2AX only in cancer cells (Figures 5A and 5C). Taken together,
these data demonstrated that the selective cancer cell killing by i-
Extract and Withanone was mediated by induction of DNA
damage and CDKN1A-p21, as predicted in Figure 3E.
We next investigated the involvement of stress response initiated
at mitochondria in i-Extract induced MCF7 cell killing. As shown
in Figures 6A and 6B, induction of ROS in the presence of i-
Extract was detected, by both immunostaining and Fluorescence
Probe (HPF) methods. Consistent with the cytotoxicity of the two
components (Withaferin A and Withanone) of i-Extract, ROS
induction was detected by both the components in MCF7 cells and
only by Withaferin A in TIG-3 cells. These data demonstrated
that the treatment with i-Extract and Withanone lead to induction
of ROS, selectively in cancer cells, hence could be responsible for
selective cancer cell killing. We next analyzed the mitochondrial
membrane potential that is highly affected by ROS levels. As
shown in Figures 6C and 6D, there was a decrease in
mitochondrial membrane potential in MCF7 cells as seen by both
JC-1 staining and Rho-123 exclusion assay. Upon treatment with
i-Extract, MCF7 cells showed shift in JC-1 staining from red to
green (Figure 6C) and negative for Rho-123 staining. Of note,
normal (TIG-3) cells were refractory to these changes when
treated with either i-Extract or Withanone (Figure 6C). These data
made us to believe that the i-Extract induced selective killing of
cancer cells involved ROS stress and mitochondrial damage. In
order to obtain more clear evidence, we examined the ultrastruc-
ture of control and i-Extract treated MCF7 cells at single-cell level.
As shown in Figure 6E, control MCF7 cells showed typical
mitochondrial morphology, characterized by a double membrane
containing a homogeneous matrix and a system of parallel cristae.
Withanone treated cells showed swollen mitochondria with an
altered morphology of which the shortening and reduction in
number of cristae were apparent (Figure 6E).
ROS are chemically reactive molecules that have essential role
in signal transduction, cell growth and differentiation, regulation
of enzyme activities and immune response including inflammation
and cytokine production. Whereas a moderate increase in ROS
promotes cell proliferation and differentiation, its excessive
amount causes irreversible oxidative damage to DNA, proteins
and lipids leading to cell death. Cancer cells frequently exhibit
high oxidative stress and increased generation of reactive oxygen
species (ROS) as compared to the normal counterparts. This
higher level of ROS serves as a selective therapeutic target by
making cancer cells vulnerable to ROS-producing reagents,
proposed as chemotherapeutic reagents [31]. A small number of
studies have presented evidence to the ROS- mediated selective
killing of cancer cells. These include, selective apoptosis in cancer
cells by avocado extract [32], beta-phenylethyl isothiocyanate
(PEITC) [33], thalidomide analogs [34] and MKT077 [35–36].
Interestingly, most of these reagents have been shown to cause
mitochondrial disfunction [31–39]. We have demonstrated, for the
first time, that the Ashwagandha leaf extract (i-Extract) and its
component, Withanone act as ROS-producing agents causing
DNA and mitochondrial damage discriminately to cancer cells,
and hence are good candidates for safe cancer therapy.
Materials and Methods
Cells and randomized hammerhead ribozyme library
screening
Human normal fibroblasts (TIG-3), breast carcinoma (MCF7),





and mouse packaging cells, PLAT-E were obtained from Japanese
Collection of Research Bioresources (JCRB) Cell Bank and
cultured in Dulbecco’s modified Eagle’s minimal essential medium
(DMEM) as described earlier [8–10]. Cells were treated with i-
Extract, Withanone and Withaferin A for 48–72 h for viability,
biochemical and visual analyses. Randomized ribozyme library
(pMX-puro/Rz) was prepared and infected into MCF7 cells as
described previously [15]. Infected cells were selected in
puromycin (2 mg/ml)-supplemented medium for 24–48 h and
were then treated with i-Extract. RNA was prepared, using Isogen
(Invitrogen), from surviving cells after 4–5 days when all the cells
in control dish had died. Total RNA (2 mg) was used for RT-PCR.
Reverse transcription was performed with lower primer (59-TTT
Ashwagandha Kill Cancer by ROS
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arrest of MCF7 cells was due to their arrest at G2 cell cycle phase (A). An increase in CDKN1A-p21 expression was seen in MCF7 cells when treated
with i-Extract and Withanone. No increase in CDKN1A-p21 expression was seen in normal cells in the presence of either i-Extract or Withanone (B and
C). Knockdown of each of the four indicated genes that compromised i-Extract induced cytotoxicity also reverted the i-Extract induced CDKN1A-p21
upregulation (D and E). HCT116 p21
2/2 cells were less sensitive to i-Extract as compared to their isogenic p21
+/+ cells. Cell viability in response to the
serially increasing concentrations of i-Extract (F).
doi:10.1371/journal.pone.0013536.g004
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transcriptase (42uC, 90 mins) and the RT-product was subjected
to PCR amplification using upper (59-tcc ccg gtt cga aac cgg gca-
39) and lower primers (94u-52u-72u/30 sec each, 20 cycles). The
amplified PCR product (,150 bp) was cloned into a TA-cloning
vector (Promega) and sequenced using T7 primer.
Gene specific shRNA-vector cloning
shRNA expression vectors for 7 genes (IGF2R, SREBF2,
AKAP11, TFAP2A, LHX3, TPX2 and ING1) were prepared as
described [15]. Two target sites were selected for each of the gene.
The target sequences selected for ING1 were ATATGAAGTT-
TAAATTCTA and GCCAAGACCTCCAAGAAGA, for TPX2
were GCAAGAAGGATGATATTAA and GGGGAAGAATG-
GAACTGGA, for TFAP2A were GGAGGAAGATCTTTAA-
GAG and GATCAAACTGTAATTAAGA, for AKAP11 were
GAGTGAAGCTTTATCAAAT and GCACAAACATGGAAA-
GTCA, for SREBF2 were GCCTCAACCTCAAACTCAG and
ATGCAAAGGTCAAAGATGA, for LHX3 were GCGAC-
GAGTTCTACCTCAT and GGGAGAGCGTTTACTGCAA,
and for IGF2R were GGCAGAAACCCAAACTGAA and GG-
AGGAAATACTACATTAA.
Cell viability assay
Human breast cancer(MCF-7) cellswere transfected with 50 ng of
the indicated plasmid DNA. After 24 h, cells were treated with i-
Extract (6 mg/ml), Withaferin A (1 mM), Withanone (25 mg/ml) for
48 h. Empty shRNA vector was used as a control. Viability of cells
was monitored by WST-based cell proliferation assay (Roche). The
doses for i-Extract and Withanone were selected based on the
Figure 5. Role of DNA damage in i-Extract induced cytotoxicity. DNA damage foci (A), induction and cH2AX phosphorylation (B)-assessed by
staining with phospho-specific antibody (100-200 cells per slide were counted) were detected in MCF7 cells treated with i-Extract, Withaferin A and
Withanone. Normal cells showed DNA damage response upon the treatment with only Withaferin A (A and C).
doi:10.1371/journal.pone.0013536.g005
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of the i-Extract and Withanone were seen to induce differentiation of
glioblastoma and neuroblastoma cells [40, and data not shown].
Western blotting
The whole cell lysate (10–20 mg) in NP40 lysis buffer obtained by
centrifugation at 10,000 rpm for 20 min at 4uC was used for immuno-
blotting as described [8]. Antibodies used were p53 (DO-1; Santa Cruz
Biotechnology), anti-mortalin [8], p21 (C-19; Santa Cruz Biotechnol-
ogy) and anti-cH2AX-Phosphorylated (Ser139) antibody (Biolegend).
Immunostaining
Cells were washed with phosphate buffered saline (PBS), fixed
with methanol:acetone (1:1), permeabilized in 0.2% PBST,
Figure 6. Role of ROS and mitochondrial damage in i-Extract induced cytotoxicity. MCF7 cells showed the induction of ROS when treated
with i-Extract, Withaferin A or Withanone (A and B). Normal cells showed ROS induction only in the presence of Withaferin A (A). Loss of mitochondrial
membrane potential in MCF7 cancer cells, as seen by JC-1 staining was detected with i-Extract only (C). Preferential induction of loss of mitochondrial
trans-membrane potential in MCF7 cells detected by flow cytometry using RHO-123 increased from 0.2% of population in control to 44% of population
treatedwithi-Extract(D).MitochondrialdamagewasdetectedinWithanone-treatedMCF7 cells.(E),Transmission electronmicroscopicimagesofcontrol
and Withanone-treated MCF7 cells. Control cells showed normal elongated mitochondrial (M) with parallel cristae (a) (enlarged boxed image, b),
Withanone-treated cells showing swollen mitochondria with reduced number of the cristae (c) (enlarged boxed image, d). N, Nucleus.
doi:10.1371/journal.pone.0013536.g006
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with first and second antibody diluted in 2% BSA/PBS [8]. For
cH2AX staining, the cells were fixed with 4% formaldehyde and
permeabilized with KCM solution (120 mM KCl, 20 mM NaCl,
10 mM Tris pH 7.5, 0.1% Triton). Blocking and antibody
preparation were done in ABDIL solution (2% BSA, 0.2%
Gelatin, 150 mM NaCl, 0.1% Triton X-100, 20 mM Tris pH 7.5,
0.1% Sodium Azide in MilliQ water).
Detection of reactive oxygen species
The reactive oxygen species were detected by fluorescent
staining using the Image-iT
TM LIVE Green Reactive Oxygen
Species (ROS) Detection Kit (Molecular Probes Inc, USA). Cells
were cultured on glass coverslips placed in 12-well plates and
treated with indicated reagents for 48 h and stained for ROS
following the procedure recommended by the manufacturers.
Quantification of the ROS production with FACS Analysis was
based on HPF (2-[6-(49-hydroxy) phenoxy-3H-xanthen-3-0n-9-
yl]benzoic acid) fluorescence. Briefly, MCF-7 cells were grown in
6-cm dish until 50% confluence, treated with i-Extract for 12 h
followed by addition of HPF (10 mM). After 4 h, cells were
washed with PBS, harvested with cell scraper. Cell fluorescence
was measured by Coulter Epic XL Flow cytometer (Beckman).
Mitochondrial membrane potential
Mitochondrial membrane potential for control and treated cells
was examined by JC-1 and RHO-123 [35] based cell-staining
assays. For JC-1 staining, MCF7 cells cultured in 24-well plates
(50–60% confluency) were treated with i-Extract for 48 h followed
by incubation with JC-1 stain (10 mg/ml) for 15 min at 37uCi n
CO2 incubator. The cells were washed with PBS and processed for
microscopy. For RHO-123 assay, MCF-7 cell were grown in 6-cm
dish until 50% confluence, treated with i-Extract for 48 h. The
treated cells were incubated with Rho123 (1 mM)-supplemented
medium for 1 h. Cells were washed with PBS and harvested with
cell-scraper. Changes in mitochondrial membrane potential were
monitored by Coulter Epic XL Flow cytometer (Beckman).
Single cell ultrastructural analysis
MCF7 cells were plated on glass coverslips. At 60% confluency,
cells were treated with Withanone for 24 h. Control and treated
cells were washed with PBS and then fixed with 1.2% glutarldehyde
in 4uC for 1 h. After post-fixation with 1% OsO4 at 4uC for 1 h,
cells were washed in PBS and dehydrated through graded ethanol
concentrations with final incubation in n-Butyl glycidyel ether for
15 min. Samples were embedded in Epoxy resin (TAAB) and were
cut into ultra-thin sections with a Reichert ultramicrotome (Leica).
The sections were stained with uranyl acetate and lead citrate and
examined with a Hitachi H-7000 electron microscope. To evaluate
mitochondrial alterations, ,50 cells per sample were observed from
two independent experiments.
Bioinformatics and statistical analyses
Pathway analysis and biological process association were
mapped using PANTHER-Expression data analysis [41,42], a
conceptually simple binomial test to compare classifications of
multiple clusters of selected list with a reference list (NCBI: Homo
sapiens Genes) to statistically determine over- or under- represen-
tation of PANTHER classification categories. Biological process
result was selected based on over-representation value and P value
less than 0.5. Protein-protein interactions for target genes were
performed with Osprey based on the General Respository for
Interaction Datasets (The GRID) and Gene onthology (GO)[43].
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